Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gardasil 9 2-Dose vs 3-Dose Regimen in Women Aged 16-45
NCT04206813Phase 4Active, not recruiting
- Sponsor
- Boston Medical Center
- Start
- Dec 2020
- Primary completion
- Apr 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by Boston Medical Center. Primary endpoints: Change in immunogenicity of Gardasil 9 at 7 months and Change in geometric mean titers ratios at 7 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT04206813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206813.